Related Experiment Video

Updated: Jun 4, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Treatments for human epidermal growth factor receptor 2 (HER2)-altered cancers evaluated using a tumor‑agnostic

Guilherme Harada1, Jamie E Chaft2, Alison M Schram2

  • 1Hospital Sírio-Libanês, Rua Dona Adma Jafet 91, São Paulo, SP 01308-050, Brazil.

Cancer Treatment Reviews
|June 2, 2026
PubMed

Insights

Human epidermal growth factor receptor 2 (HER2) targeted therapies show promise in pan-tumor approaches. However, efficacy varies due to tumor-specific factors, necessitating careful consideration in clinical research.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Research

Background:

  • Human epidermal growth factor receptor 2 (HER2) is a key driver in various cancers.
  • HER2 therapies represent a shift towards biomarker-driven, pan-tumor treatment strategies.
  • Understanding HER2's role is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To review the efficacy of approved and emerging HER2 therapies in tumor-agnostic studies.
  • To highlight factors influencing HER2 therapy variability across different cancer types.
  • To inform future clinical research on HER2-altered cancers.

Main Methods:

  • Review of existing data on HER2 therapies in tumor-agnostic settings.
  • Analysis of factors contributing to differential treatment outcomes.
  • Evaluation of the strengths and limitations of tumor-agnostic basket trials.

Main Results:

  • HER2 therapies demonstrate potential in broad cancer applications.
  • Efficacy of HER2 therapies is influenced by tumor heterogeneity, co-alterations, and resistance mechanisms.
  • Tumor-agnostic trials provide efficient evaluation but face challenges in reliability due to design and patient population.

Conclusions:

  • HER2-targeted treatments offer a promising avenue for pan-tumor oncology.
  • Variability in response necessitates a deeper understanding of tumor-specific biology.
  • Future research should address the limitations of current trial designs to optimize HER2 therapy utilization.
Keywords:
HER2 therapyHER2-altered cancerHuman epidermal growth factor receptor 2 (HER2)Tumor-agnostic

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...